$ATRC News

Insider Selling: Vinayak Doraiswamy Unloads $233K Of AtriCure Stock

Board Member At AtriCure Exercises Options Worth $491K

AtriCure, Inc. 2026 Q2 - Results - Earnings Call Presentation

UBS Maintains Buy on AtriCure, Lowers Price Target to $50

AtriCure, Inc. (ATRC) Q2 2026 Earnings Call Transcript

AtriCure (NASDAQ:ATRC) Profitability Surge Drives After-Hours Rally Despite Inline Revenue

AtriCure Reports Q2 2026 Results: Full Earnings Call Transcript

AtriCure Raises FY2026 GAAP EPS Guidance from $0.00-$0.04 to $0.05-$0.13 vs $0.05 Est

AtriCure Q2 Adj. EPS $0.18 Beats $0.00 Estimate, Sales $153.600M Beat $151.842M Estimate

AtriCure Raises FY2026 Adj EPS Guidance from $0.00-$0.04 to $0.24-$0.32 vs $0.06 Est; Raises FY2026 Sales Guidance from $600.000M-$610.000M to $602.000M-$610.000M vs $604.990M Est

AtriCure, Inc. (ATRC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

AtriCure, Inc. (ATRC) Presents at Bank of America Global Healthcare Conference 2026 Transcript

AtriCure, Inc. 2026 Q1 - Results - Earnings Call Presentation

Canaccord Genuity Maintains Buy on AtriCure, Raises Price Target to $55

AtriCure, Inc. (ATRC) Q1 2026 Earnings Call Transcript

AtriCure (NASDAQ:ATRC) Q1 Results Beat Estimates as Company Reaches Key Profitability Milestone

AtriCure Q1 2026 Earnings Call Transcript

AtriCure Lowers FY2026 Adj EPS Guidance from $0.09-$0.15 to $0.00-$0.04 vs $0.07 Est; Affirms FY2026 Sales Guidance of $600.000M-$610.000M vs $604.053M Est

AtriCure Q1 Adj. EPS $0.00 Beats $(0.06) Estimate, Sales $141.249M Beat $139.812M Estimate

AdaptHealth (AHCO) Surges 10.7%: Is This an Indication of Further Gains?